Humanized Advantage Cyagen’s HUGO-GT whole genome humanized model and HUGO-Ab mice provide human-relevant preclinical platforms that can shorten development timelines and improve prediction of efficacy and safety; position as premium tooling for pharma partners and offer bundled services spanning target validation, model generation, and preclinical testing.

Strategic Partnerships Recent alliances with Taconic and Biointron demonstrate Cyagen’s ability to expand model access and integrate advanced discovery platforms; target large biotech and pharma customers seeking diverse, scalable preclinical models and antibody discovery capabilities.

AI Powered Discovery AI-enabled platforms such as the rare disease database and AbSeek antibody tool enhance hit discovery and candidate selection; pitch to oncology, autoimmune, and rare disease programs to accelerate lead generation.

Global Reach A broad global footprint and deep capability across neurological diseases, oncology, metabolic disorders, ophthalmology, and autoimmune conditions enable cross-selling of end-to-end CRO services to multi-therapy programs and global clients.

Full Service Cyagen’s end-to-end CRO offering from target validation through preclinical research reduces vendor fragmentation and procurement risk; propose bundled engagements, program management, and regulatory-ready data packages to streamline client deployments.